Search clinical trials for: Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin

Total 1185 results

Li Zhang, MD

Recruiting

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer

Biliary Tract Cancer

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

Small Cell Lung Carcinoma

China
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

Ampullary Carcinoma
Fudan University

Unknown

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Thyroid Cancer

China
BeiGene

Completed

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC

Non-Small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Stage II-III Non-small Cell Lung Cancer

China
Peking University

Recruiting

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Refractory Metastatic Digestive System Carcinoma

China
Zhejiang University

Recruiting

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Colorectal Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
Pfizer

Completed

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

NSCLC (Non-small Cell Lung Cancer)

Hong Kong, China, Taiwan, Malaysia, Thailand
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Innate Pharma

Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Non Small Cell Lung Cancer

France, United States, Greece, Hungary, Poland
Sichuan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer

Non-squamous Non-small-cell Lung Cancer | Anlotinib

China
AstraZeneca
Parexel

Active, not recruiting

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COMPEL)

Non-small Cell Lung Cancer

Italy, Spain, United States, China, Germany, Israel
Fujian Cancer Hospital

Not yet recruiting

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

EGFR Positive Non-small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Ruijin Hospital

Recruiting

Combination Therapy for First Line Treatment of Advanced Cervical Cancer

Advanced Cervical Cancer

China
AstraZeneca

Active, not recruiting

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Non Small Cell Lung Carcinoma NSCLC

Poland, Taiwan, Thailand, Vietnam, United States, Korea, Republic of, Hungary, Russian Federation, Turkey, China, Australia, Netherlands
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Non Small Cell Lung Cancer
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Poland, India, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Lung Cancer | Non Small Cell Lung Cancer | Apatinib | Combination Chemotherapy

China
Shanghai Chest Hospital

Unknown

To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Radiotherapy | Non-small Cell Lung Cancer Stage IIIA

China
Eli Lilly and Company

Completed

Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

France, Germany, Spain
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
AstraZeneca

Active, not recruiting

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2)

Non-Small Cell Lung Cancer

United States, Canada, Thailand, Vietnam, France, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, Russian Federation, China, Taiwan, United Kingdom, Czechia, Chile, Australia, Argentina, Slovakia, South Africa
Shanghai Chest Hospital
Fudan University; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaborators

Unknown

To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Radiotherapy | Non-small Cell Lung Cancer Stage IIIA

China
Sichuan Cancer Hospital and Research Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Lung Cancer Metastatic

China
ImmunityBio, Inc.

Active, not recruiting

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Non Small Cell Lung Cancer

United States
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Suzhou Puhe Pharmaceutical Technology Co., LTD

Not yet recruiting

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

China
SCRI Development Innovations, LLC
Pfizer

Withdrawn

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer

United States
AstraZeneca
Parexel

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)

Non-small Cell Lung Cancer

Hungary, United States, Italy, Belgium, Spain, France, Korea, Republic of, Taiwan, Turkey, Ireland, Portugal, Canada
Sun Yat-sen University

Active, not recruiting

Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. (NAJSCR)

Efficacy and Safety

China
Sun Yat-sen University

Active, not recruiting

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Nasopharyngeal Carcinoma

China
Shandong Cancer Hospital and Institute

Recruiting

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unresectable Stage III NSCLC

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Non-Small Cell Lung Cancer
Eli Lilly and Company

Completed

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

Non-Small-Cell Lung Cancer

United States, India
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Toripalimab for High-risk Locally Advanced Cervical Cancer

Cervical Cancers

China
AstraZeneca

Active, not recruiting

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)

Non-Small-Cell Lung Carcinoma NSCLC

United States, Belgium, Spain, Canada, Taiwan, Thailand, Vietnam, France, Germany, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, Netherlands, Australia, Switzerland
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

Treatment | Histological Type of Neoplasm | Lung Adenocarcinoma, Stage I | Chemotherapy, Adjuvant

China
Anhui Provincial Hospital

Unknown

Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma

Adenocarcinoma of Lung

China
Hutchison Medipharma Limited

Recruiting

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification (SACHI)

Non-small Cell Lung Cancer

China
Avistone Biotechnology Co., Ltd.

Not yet recruiting

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Non-Small-Cell Lung Cancer
Taizhou Hanzhong biomedical co. LTD

Recruiting

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Nonsquamous Non-small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China

Search clinical trials for: Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations